ERBB2 and breast cancer: A recent paper analyzing 12,439 tumor samples, 8,775 of which were ER+ showed that for ER+ tumors that express HER-2, the presence of intratumor CD8+ T cells was associated with a 27% reduction in the hazard of dying from breast cancer (48).